Lower fasting-ghrelin-levels (FGL) are associated with obesity and metabolic syndrome. We aimed to explore the dynamics of FGL during weight-loss and its metabolic and adiposity-related manifestations beyond weight-loss. MethodsA secondary analysis of a clinical trial where we randomized participants with abdominal-obesity/dyslipidemia to one of three diets: healthy-dietary-guidelines (HDG), Mediterranean diet (MED), or green-MED diet, all… Continue reading #Diet-induced #fasting ghrelin elevation reflects the recovery of #insulin sensitivity and visceral adiposity regression
Category: Endocrinology
Cardiovascular health, genetic predisposition, and lifetime risk of type 2 #diabetes
Data on the lifetime risk of type 2 diabetes (T2D) incidence across different cardiovascular health (CVH) categories are scarce. Moreover, it remains unclear whether a genetic predisposition modifies this association. Methods and resultsUsing data from the prospective population-based Rotterdam Study, a CVH score (body mass index, blood pressure, total cholesterol, smoking status, diet, and physical… Continue reading Cardiovascular health, genetic predisposition, and lifetime risk of type 2 #diabetes
Fasting plasma #glucose level in the range of 90 to 99 mg/dL and the risk of the onset of type 2 #diabetes: Population-based Panasonic cohort study 2
As the association between fasting glucose concentration from 90 to 99 mg/dL and the onset of type 2 diabetes is still controversial, we aimed to assess it in 37,148 Japanese individuals with normal plasma glucose concentration. Materials and MethodsThis long-term retrospective cohort study included individuals with medical checkup at Panasonic Corporation from 2008 to 2018.… Continue reading Fasting plasma #glucose level in the range of 90 to 99 mg/dL and the risk of the onset of type 2 #diabetes: Population-based Panasonic cohort study 2
Effects of #SGLT-2 inhibitors on serum #uric acid in patients with T2DM: A systematic review and network meta-analysis
The present study aims to determine the effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitors on the serum uric acid (SUA) levels of patients with type 2 diabetes mellitus (T2DM) in Asia. MethodsPubMed, CENTRAL, Embase and Cochrane Library databases were searched for randomized controlled trials (RCTs) of SGLT-2 inhibitors in patients with T2DM up to July… Continue reading Effects of #SGLT-2 inhibitors on serum #uric acid in patients with T2DM: A systematic review and network meta-analysis
#Proteinuria as a Significant Predictive Factor for the Progression of Carotid Artery #Atherosclerosis in Non-Albuminuric Type 2 #Diabetes
The purpose of this study was to evaluate whether the urine protein to creatinine ratio (uPCR) has have clinical significance in relation to cardiovascular risk associated with carotid artery intima-media thickness (cIMT) progression, in subjects with type 2 diabetes and normoalbuminuria. MethodsIn this retrospective longitudinal study on T2D, we recruited 927 subjects with normoalbuminuria (urine… Continue reading #Proteinuria as a Significant Predictive Factor for the Progression of Carotid Artery #Atherosclerosis in Non-Albuminuric Type 2 #Diabetes
Association of #Statin Therapy Initiation With #Diabetes ProgressionA Retrospective Matched-Cohort Study
Statin therapy has been associated with increased insulin resistance; however, its clinical implications for diabetes control among patients with diabetes is unknown. Objective To assess diabetes progression after initiation of statin use in patients with diabetes. Design, Setting, and Participants This was a retrospective matched-cohort study using new-user and active-comparator designs to assess associations between… Continue reading Association of #Statin Therapy Initiation With #Diabetes ProgressionA Retrospective Matched-Cohort Study
#Bone mineral density and bone turnover ten years after a single 5mg dose or two 5-yearly lower doses of #zoledronate in osteopenic older women: an open-label extension of a randomized controlled trial
Intravenous zoledronate reduces fracture risk (5mg at 18mo intervals) and prevents bone loss (doses of 1-5mg for 3 to >5y), but the duration of action of a single 5mg dose and the effects of lower doses beyond 5 years are unknown. We report the second open-label extension (years 5-10) of a 2y randomized, multidose, placebo-controlled, double-blinded… Continue reading #Bone mineral density and bone turnover ten years after a single 5mg dose or two 5-yearly lower doses of #zoledronate in osteopenic older women: an open-label extension of a randomized controlled trial
#Aging and comorbidities influence the risk of hospitalization and mortality in #diabetic patients experiencing severe hypoglycemia
Severe hypoglycemia requiring access to the Emergency Department is more frequent in older patients with multiple comorbidities.•Risk of hospitalization and mortality within one year since the hypoglycemic event is higher in older frail patients.•Severe hypoglycemia could increase the cardiovascular risk and could be a marker of future cardiovascular events.•A less stringent glycemic control and the… Continue reading #Aging and comorbidities influence the risk of hospitalization and mortality in #diabetic patients experiencing severe hypoglycemia
Incident Major #Depressive Disorder Predicted by Three Measures of Insulin #Resistance: A Dutch Cohort Study
Major depressive disorder is the leading cause of disability worldwide. Yet, there remain significant challenges in predicting new cases of major depression and devising strategies to prevent the disorder. An important first step in this process is identifying risk factors for the incidence of major depression. There is accumulating biological evidence linking insulin resistance, another… Continue reading Incident Major #Depressive Disorder Predicted by Three Measures of Insulin #Resistance: A Dutch Cohort Study
2 Medical News 